Wang, J.; Susam, M.M.; Gan, C.; Sparidans, R.W.; Lebre, M.C.; Beijnen, J.H.; Schinkel, A.H.
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure. Pharmaceuticals 2022, 15, 1124.
https://doi.org/10.3390/ph15091124
AMA Style
Wang J, Susam MM, Gan C, Sparidans RW, Lebre MC, Beijnen JH, Schinkel AH.
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure. Pharmaceuticals. 2022; 15(9):1124.
https://doi.org/10.3390/ph15091124
Chicago/Turabian Style
Wang, Jing, M. Merve Susam, Changpei Gan, Rolf W. Sparidans, Maria C. Lebre, Jos H. Beijnen, and Alfred H. Schinkel.
2022. "P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure" Pharmaceuticals 15, no. 9: 1124.
https://doi.org/10.3390/ph15091124
APA Style
Wang, J., Susam, M. M., Gan, C., Sparidans, R. W., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H.
(2022). P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure. Pharmaceuticals, 15(9), 1124.
https://doi.org/10.3390/ph15091124